Kirsten Detrick

Kirsten Detrick currently serves as the Chief Representative, USA at Basel Area Business & Innovation, advising US life sciences companies on expansion into Switzerland and the Basel Area. Detrick is also the Chief Executive Officer of a Stealth Mode Biotech focused on lysosomal storage diseases and co-founder of a Stealth venture addressing SARS-CoV-2. Additionally, Detrick teaches as an Adjunct Professor of Business at The Tuck School of Business at Dartmouth and is the Founder and CEO of Parke-Hadley Advisors, providing strategic guidance to emerging biopharma firms. Previous roles include Chief Commercial Officer at ENDPOINT HEALTH, Board Member at Orexo AB publ, and various leadership positions at Takeda and Amgen, with extensive experience in commercialization, marketing, and strategic planning across the biotechnology and pharmaceutical industries. Academic qualifications include an MBA from The Tuck School of Business at Dartmouth and a BA in Chemistry from Middlebury College.